Josef von Rickenbach Net Worth: Researched Estimate & Assets

Josef von Rickenbach's net worth is estimated at approximately $50 million to $80 million, based on documented equity dispositions from public SEC filings, the 2017 $5.0 billion acquisition of PAREXEL International, and subsequent director-level positions at small-cap biotechnology companies. No audited personal financial statement is publicly available, so this range is a best-effort figure anchored to verifiable events rather than a precise declaration. Automated aggregators such as Benzinga have placed the figure closer to $45.6 million based solely on reported stock positions, but that number almost certainly undercounts realized proceeds from the PAREXEL buyout and private holdings.

Quick Net Worth Summary

The most defensible estimate for Josef H. von Rickenbach's net worth sits in the $50 million to $80 million range as of mid-2026. See also our related coverage on Joseph Ruskin net worth for a comparable public-figure wealth estimate. The lower bound is anchored by SEC Form 4 disclosures showing approximately 503,329 PAREXEL shares disposed at $88.10 per share in the 2017 Pamplona Capital Management buyout, implying gross proceeds in the neighborhood of $44 million from that transaction alone. The upper bound accounts for additional equity accumulated over a 35-year tenure as CEO and Chairman, the HelioVision liquidity event in 2019, investment income, and assets not captured in public filings. Confidence in this range is moderate: public records confirm the career arc and specific transactions, but no comprehensive personal balance sheet is on record.

Snapshot: Key Financial Facts

Short Biography and Career Highlights

Josef H. von Rickenbach, known professionally as Joe, was born in November 1954 and holds American nationality. He earned a Bachelor of Arts from the University of Lucerne and an M.B.A. from Harvard Business School, the latter providing the network and analytical foundation that shaped his subsequent career in the contract research organization (CRO) industry.

In 1982, von Rickenbach co-founded PAREXEL International, a clinical research and regulatory affairs firm that would grow into one of the largest CROs in the world. He served as CEO and Chairman for decades, steering the company through its initial public offering, multiple secondary offerings, and a long run as a publicly traded entity on Nasdaq under the ticker PRXL. That tenure is directly linked to the bulk of his estimated wealth: every year the company grew, the value of his equity stake grew with it. PAREXEL eventually employed tens of thousands of people across more than 100 countries before being taken private.

After leaving PAREXEL following its 2017 going-private transaction, von Rickenbach co-founded HelioVision, a private ophthalmology company. HelioVision was acquired by Aldeyra Therapeutics in January 2019, with von Rickenbach named as the securityholder representative in the merger agreement. He subsequently moved into board roles at early-stage biotechs, including Rein Therapeutics (RNTX, where he became a director in June 2019) and Javara, a research site organization. SEC Form 4 filings from as recently as May 2026 show small open-market purchases of RNTX shares, confirming his continued active engagement with public-company governance.

Primary Income Sources and Revenue Streams

Equity and Salary from PAREXEL (1982–2017)

The dominant income source across von Rickenbach's career was his founder and executive equity in PAREXEL. As co-founder, CEO, and Chairman, he held shares accumulated through founding grants, restricted stock awards, and option exercises disclosed in annual proxy filings over more than two decades. CEO compensation at large publicly traded CROs routinely includes base salaries in the $1 million to $2 million range plus performance bonuses and annual equity grants. While PAREXEL's specific compensation detail for each year of his tenure is not reproduced here, its proxy statements (filed annually with the SEC) represent the best on-record source for those figures.

PAREXEL Buyout Proceeds (2017)

The single most significant documented liquidity event is the 2017 Pamplona Capital Management acquisition of PAREXEL at $88. PAREXEL 8‑K (press release) & related SEC exhibits documenting $88.10 per share deal; Aldeyra 10‑K documents HelioVision acquisition (see SEC 8‑K filing for PRXL dated 2017 for the $88.10/share Pamplona transaction). 10 per share, valuing the company at approximately $5.0 billion including net debt. SEC Form 4 activity aggregated for von Rickenbach's CIK (0001007706) shows dispositions of approximately 503,329 common shares in the September to October 2017 transaction window, implying gross proceeds of roughly $44.3 million from that tranche alone. It is important to note that Form 4 disclosures capture reported transactions but may not reflect all shareholdings converted in the deal, including shares held in trusts or through other vehicles not individually reported at his CIK.

HelioVision and Aldeyra Consideration (2019)

As a co-founder and securityholder representative for HelioVision, von Rickenbach was party to Aldeyra's acquisition agreement, which provided for up to 5,248,885 Aldeyra common shares as contingent consideration, including $2.5 million in stock issued 24 months after closing and additional tranches tied to FDA approval milestones. The precise dollar value of his personal allocation depends on his ownership percentage in HelioVision, which is not publicly disclosed. This event adds an uncertain but real increment to his total realized wealth.

Director Compensation and Current Holdings

Board director roles at companies like Rein Therapeutics typically provide annual cash retainers in the $40,000 to $80,000 range plus equity grants, though specific current compensation details for von Rickenbach at RNTX and Javara are not fully itemized in available public filings. His May 2026 Form 4 filings confirm ongoing open-market share purchases at Rein Therapeutics, indicating continued personal investment in entities where he holds influence.

Investment Income and Other Assets

A person who realized tens of millions of dollars from a going-private transaction in 2017 would typically deploy that capital into diversified investments, including market securities, private equity, and real estate. No public filings enumerate these holdings for von Rickenbach, but their probable existence is factored into the upper range of the net worth estimate here.

Major Assets and Valuations

Public records do not provide a comprehensive inventory of Josef von Rickenbach's personal assets. What can be verified from open sources is limited to securities positions reported via SEC Form 4 filings. As of the most recent available filings in 2026, he holds a quantifiable but modest position in Rein Therapeutics (RNTX), a small-cap biotech, and is affiliated with Javara as a director or investor. His UK company appointment history (Heron Group Limited, April 2013 to March 2018, per Companies House records) suggests he has or had international business interests, though the nature and value of that involvement are not publicly disclosed.

Real estate holdings, if any, are not discoverable from SEC filings or the public corporate record. Aircraft, yachts, private equity fund interests, trusts, and other off-registry holdings remain entirely private. These gaps mean the verified asset list is necessarily incomplete and the true figure could be materially higher than the estimate presented here.

Business Affiliations, Board Roles and Ownership Stakes

Major Financial Events and Legal Matters

PAREXEL IPO and Public Market Run

PAREXEL went public during the expansion of the CRO sector in the 1990s, with von Rickenbach's founder equity transitioning from illiquid private shares to publicly traded stock. Each secondary offering and equity grant during the company's multi-decade Nasdaq tenure progressively refined the value of his holdings. The specifics of each offering are on record in historic EDGAR filings for PRXL but are too numerous to enumerate individually here.

2017 Pamplona Acquisition (Primary Liquidity Event)

The $5.0 billion Pamplona Capital Management acquisition, announced via PAREXEL's 8-K filing, is the most significant financial event in von Rickenbach's career from a personal wealth perspective. The per-share price of $88.10 was fixed, meaning all PRXL shareholders, including founder executives, received that price for any shares tendered. The transaction closed in 2017 and effectively ended his operating role at the company he had led for 35 years.

HelioVision / Aldeyra Merger (2019)

Aldeyra Therapeutics acquired HelioVision in a deal that closed January 28, 2019. Aldeyra's 10-K and related filings describe the contingent share structure and identify von Rickenbach as the securityholder representative, giving him a formal, documented role in the transaction. The economic benefit to him personally depends on his undisclosed ownership stake in HelioVision.

Legal Matters

No material personal legal judgments, regulatory enforcement actions, or significant disclosed litigation involving Josef von Rickenbach as an individual have been identified in publicly available records as of July 2026. Readers or journalists researching this area should check PACER for federal civil case records and relevant state court databases directly.

Chronological Financial Timeline and Net Worth Trajectory

1. 1982: Co-founds PAREXEL International — initial equity stake is illiquid, pre-revenue; personal net worth at this stage is negligible from the company alone.
2. 1990s: PAREXEL goes public on Nasdaq (PRXL); founder equity becomes publicly traded and liquid for the first time; SEC proxy filings begin documenting executive compensation. Net worth begins to grow materially with stock price appreciation.
3. 2000s: PAREXEL expands globally; von Rickenbach's role as CEO/Chairman of a large-cap CRO means annual compensation packages (salary, bonus, equity grants) compound the position year over year. Specific per-year figures are in historic PRXL proxy statements on SEC EDGAR.
4. 2013: Appointed to Heron Group Limited (UK) — indicates international business activity; no public valuation available for this role.
5. 2017 (September–October): PAREXEL acquired by Pamplona Capital Management at $88.10/share in a ~$5.0B transaction. Form 4 activity on CIK 0001007706 shows approximately 503,329 shares disposed in this window, implying gross proceeds of ~$44.3M from this tranche. This is the most important single verified data point in the net worth calculation. Post-tax net from this event alone could be in the $30M–$35M range depending on cost basis and applicable tax rates.
6. 2018: Heron Group Limited directorship ends (Companies House, March 2018). Co-founds HelioVision around this period.
7. 2019 (January): HelioVision acquired by Aldeyra Therapeutics; von Rickenbach serves as securityholder representative. Contingent stock consideration of up to 5,248,885 Aldeyra shares adds an uncertain increment to total wealth.
8. 2019 (June): Joins Rein Therapeutics (RNTX) board as director; begins accumulating a disclosed RNTX equity position.
9. 2020–2025: Continues as RNTX director; multiple Form 4 filings record open-market share purchases — these are relatively small transactions consistent with a director-level rather than founder-level stake.
10. May 2026: Most recent available Form 4 filings for CIK 0001007706 show continued activity at Rein Therapeutics. No other major liquidity events are on public record during this period.
11. Data gap note: Between the IPO in the 1990s and the 2017 buyout, annual changes in PRXL stock price and changes to von Rickenbach's share count (grants, exercises, sales) would have caused year-to-year fluctuations that are documented in historic proxy statements and Form 4s but are not reconstructed in full here due to the volume of filings.

How the Estimate Was Derived and Supporting Evidence

The $50 million to $80 million range was built from the bottom up using publicly available documents as anchors. The methodology follows standard practice for estimating wealth when no personal financial disclosure exists: start with documented realized proceeds from public filings, apply reasonable assumptions for items not directly disclosed, and flag where assumptions are needed.

• Anchor point 1 (PAREXEL 2017 disposal): SEC Form 4 aggregate data for CIK 0001007706 shows approximately 503,329 PRXL shares disposed at $88.10 in the 2017 transaction window. Gross proceeds: ~$44.3M. Estimated post-tax proceeds (assuming long-term capital gains on a significant portion): ~$30M–$35M.
• Anchor point 2 (executive compensation, 1990s–2017): Decades of base salary, annual bonuses, and periodic equity grants as CEO/Chairman of a large publicly traded CRO represent a material cumulative income stream. Without reconstructing every proxy filing, this is estimated at a floor contribution of $10M–$20M in after-tax earnings and reinvested savings over the period.
• Anchor point 3 (HelioVision / Aldeyra): The contingent equity consideration tied to FDA milestones introduces uncertainty. A conservative placeholder of $1M–$5M is used, subject to milestone achievement and Aldeyra's stock price at issuance.
• Anchor point 4 (investment returns, 2017–2026): A nine-year investment horizon on $30M–$40M of realized proceeds, conservatively managed at a blended 5–7% annual return, would compound the base materially. This supports the upper end of the range.
• Aggregator cross-check: Benzinga's algorithmic estimate of ~$45.6M is treated as a conservative floor because it is derived only from reported stock positions, not from proceeds of the 2017 buyout.
• Confidence level: Moderate. The PAREXEL proceeds are the most verifiable component, but the exact share count at closing (including all vehicles) is not fully reconstructed from available Form 4 data. The investment and compensation components rely on informed assumptions rather than disclosed figures.

Recent Developments and Factors That Could Change the Estimate

As of July 2026, the factors most likely to move von Rickenbach's net worth estimate materially are concentrated in three areas. First, Rein Therapeutics (RNTX) is a small-cap biotech where he holds both a board seat and a personal equity position confirmed by 2026 Form 4 activity. A successful clinical outcome or acquisition of RNTX could generate a meaningful return; conversely, clinical failure or delisting could reduce that position to near zero. Small-cap biotech outcomes are binary by nature, and this exposure adds volatility to the top end of the estimate.

Second, the contingent Aldeyra Therapeutics shares tied to HelioVision's FDA milestone performance remain an open variable. If milestones were achieved and shares issued, the value realized depends on ALDX's stock price at the time of issuance and any subsequent holding or disposal decisions, none of which are captured in currently available public filings.

Third, macroeconomic factors affecting the broader investment portfolio (if any) accumulated since 2017 would affect the estimate in either direction. Rising or falling equity markets, interest rate changes affecting real estate values, and private equity fund performance are all plausible exposures for someone who realized a large liquidity event nine years ago. None of these can be tracked from public records.

Comparative Context: Related R-Named Figures

Placing von Rickenbach's estimated wealth in context is useful for readers who arrived here through broader research on R-named public figures. His career profile, as a founder-executive who built significant wealth through a single dominant company over decades before diversifying into smaller ventures, differs considerably from the profiles of others covered on this site. Adolph Rickenbacker, the guitar and electric instrument innovator, built his fortune through manufacturing and intellectual property in a completely different era and industry. Daniel Rickenmann, a political figure, represents the public-service side of the R-names category, where compensation structures and wealth accumulation follow an entirely different logic. Related coverage includes a dedicated summary of Daniel Rickenmann net worth. Joseph Rivet and Joseph Ruskin represent entertainment and performing-arts trajectories where career earnings are structured around project fees, royalties, and residuals rather than founder equity in a multi-billion-dollar corporation. Massimo Rivola, linked to motorsport management, operates in the event-driven commercial world of professional racing. For readers interested in a motorsport executive comparison, see Massimo Rivola net worth for a profile of that figure's financials and career earnings. Von Rickenbach's case is most analogous, structurally, to a biotech or professional services founder, making him a distinct data point within this curated group.

Limitations, Reliability Notes, and Requests for Further Records

The most important limitation of this profile is the absence of any publicly available, audited personal financial statement for Josef von Rickenbach. Everything presented here is constructed from corporate filings (SEC Form 4s, 8-Ks, 10-Ks, proxy statements) and public register records (Companies House, UK). These documents confirm transaction prices and specific securities dispositions but do not constitute a personal balance sheet.

Specific gaps that a researcher or journalist should be aware of include: the exact number of PRXL shares von Rickenbach held at the close of the 2017 Pamplona transaction (including any held in trusts, family vehicles, or accounts not tied to his personal SEC filings); the precise ownership percentage he held in HelioVision and therefore his allocation of the Aldeyra merger consideration; any real estate holdings (which would appear in county property records, not SEC filings); any private equity fund interests or family office structures; and any liabilities, mortgages, or personal debt obligations.

Readers seeking to verify or refine this estimate should consult: SEC EDGAR directly at CIK 0001007706 for all Form 4 and historic PRXL proxy filings; the Aldeyra Therapeutics 10-K filings disclosing the HelioVision acquisition terms; Companies House (UK) for the Heron Group Limited directorship record; PACER for any federal civil litigation; and county-level property records in locations where von Rickenbach is known to reside. Any journalist or researcher who obtains additional primary documentation is encouraged to update or correct the public record accordingly.